<DOC>
	<DOCNO>NCT01329809</DOCNO>
	<brief_summary>This neoadjuvant Phase 2a , open-label trial patient metastatic colorectal carcinoma undergo complete resection metastatic colorectal tumor liver .</brief_summary>
	<brief_title>Neoadjuvant Study Recombinant Vaccinia Virus Treat Metastatic Colorectal Carcinoma Patients Undergoing Complete Resection Liver Tumors</brief_title>
	<detailed_description>Patients receive either intravenous infusion intratumoral injection JX-594 ( Pexa-Vec ) directly one liver lesion Day 1 . Patients undergo complete resection liver tumor Day 15 . Patients monitor throughout life disease recurrence and/or general overall survival .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Vaccinia</mesh_term>
	<criteria>The planned surgical resection must margin negative complete resection resection plus radiofrequency ablation ( RFA ) metastatic CRC determine principal investigator surgeon Diagnosis histologicallyconfirmed metastatic colorectal tumor ( ) within liver eligible surgical resection . Eligible patient must : preoperative workup reveals potential resectability ( CT scan MRI abdomen pelvis CT scan chest within 6 week enrollment ) preoperative workup ensure operability general medical clearance indicate At least one measurable tumor mass MRI ( i.e . lesion accurately measure least one dimension long diameter ≥ 1 cm ) Plan maximum resection six ( 6 ) liver segment Child Pugh A ( Refer APPENDIX C : ChildPugh Classification Performance Score : KPS score ≥ 70 Age ≥18 year For patient treat IT injection : least 1 intrahepatic tumor long diameter ( LD ) ≥ 1.5 cm ≤ 12 cm technically amenable injection radiographic guidance target surgical resection . In patient treat IT injection , injected tumor must include surgical resection specimen ( plan RFA injected tumor would eligible ) Total bilirubin ≤ 3 x ULN AST , ALT &lt; 5.0 x ULN WBC ≥ 3.5x 109/L ≤ 50 x 109/L ANC ≥1.5 x 109/L CD4 ≥ 200 total cells/mm3 Hemoglobin ≥ 80g/L Platelet count ≥ 100 x 109/L Acceptable coagulation status : INR ≤ 1.4 Creatinine ≤ 2 x ULN Serum Sodium , Potassium Calcium level ≤ Grade 1 If patient diabetic screen random glucose &gt; 8.9mmol/L , fast glucose must do result must WNL Grade 1 order eligible study . For patient sexually active : patient must able willing abstain sex JX594 treatment period ( prevent pregnancy ) willing use barrier method least 6 week last JX594 treatment ( protect partner infection ) . Able willing sign Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) /Research Ethics Board ( REB ) approve write consent form Able willing comply study procedure followup examination , include compliance `` Infection Control Guidelines Patients '' contain within write consent form . Prior localregional treatment ( include hepatic arterial infusion , hepatic embolization , radiofrequency ablation ) tumor downstaging . Prior adjuvant chemotherapy accept long duration chemotherapy development metastases &gt; 8 week . Pregnant nursing infant Known myeloproliferative disorder require systemic therapy Significant immunodeficiency due underlie illness ( e.g . HIV/AIDS ) and/or medication ( e.g . high dose systemic corticosteroid take 4 week within precede 3 month ) History severe exfoliative skin condition ( e.g . eczema atopic dermatitis require systemic therapy 4 week ) Tumor ( ) invade major vascular structure ( e.g . carotid artery ) Clinically significant and/or rapidly accumulate ascites , pericardial and/or pleural effusion Clinically significant active infection , require systemic antibiotic therapy , uncontrolled medical condition would , opinion principle investigator , impair ability subject receive protocol therapy Severe unstable cardiac disease , include significant coronary artery disease require angioplasty stenting within precede 12 month , unless wellcontrolled stable medical therapy least 3 month Known viable CNS malignancy ( history completely resect irradiated brain metastasis allow ) Chronic use antiplatelet anticoagulation medication temporarily discontinue least seven day prior treatment JX594 . ( Note : following allow : low dose aspirin ≤ 100 mg , low dose coumadin long INR ≤ 1.4 lowdose heparin maintain port access ) Use follow antiviral agent : ribavirin , adefovir , cidofovir ( least 7 day prior first treatment ) , PEGIFN ( least 14 day prior first treatment ) . Absolute contraindication undergo MRI scanning ( e.g . pacemaker , paramagnetic intracranial aneurysm clip , inner ear implant , fragment metal within body , etc. ) . Pulse oximetry O2 saturation &lt; 90 % rest Experienced severe systemic reaction sideeffect result previous smallpox vaccination Inability unwillingness give informed consent comply procedure require protocol . Patients household contact meet criterion exclude unless alternate living arrangement make patient 's dosing period least 7 day follow last dose study medication Pregnant nursing infant Children &lt; 1 year old People skin disease ( eczema , atopic dermatitis relate disease Immunocompromised host ( severe deficiency cellmediated immunity , include AIDS , organ transplant recipient , hematologist malignancy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>metastatic colorectal cancer</keyword>
	<keyword>colon cancer</keyword>
	<keyword>liver metastasis</keyword>
	<keyword>Pexa-vec</keyword>
	<keyword>JX-594</keyword>
</DOC>